MedBiome Licenses the RapidAIM Technology Targeting the Microbiome to

Improve Human Health

MedBiome accelerates the development of drugs targeting the gut microbiome. The RapidAIM
technology enables rapid screening of the effects of compounds on live individual human
microbiomes in 96 well plates.

Ottawa, Canada, January 30, 2020 --(PR.com)-- MedBiome Inc. is pleased to announce that it has
exclusively licensed the RapidAIM technology from the University of Ottawa. RapidAIM is a
revolutionary assay to rapidly determine the effects of compounds on individual human living
microbiomes. RapidAIM fidelity maintains functional living human microbiomes in 96 well plates and
allows the testing of drugs for their effects on the microbiome for up to 5 days. RapidAIM is used to
identify compounds that change the composition of the human microbiome, promote the productions of
specific metabolites by the human microbiome and for the stratification of patients based on their
microbiome responses. MedBiome is using the RapidAIM technology to identify microbiome metabolic
modulators that promote the production of specific metabolites in Inflammatory Bowel Disease,
Alzheimer's Disease, Chronic kidney disease and Colorectal cancer. MedBiome also provides access to
RapidAIM through partnerships.

MedBiome Inc., www.MedBiome.ca, is a biopharmaceutical company focusing on 1) discovering and

developing microbiome-targeted therapeutics and nutritional products to modulate the microbiome
composition and the production of metabolites beneficial to the host and 2) partnering with biotechnology
and pharmaceutical companies seeking to screen their proprietary drugs/compounds against
human/animal microbiomes. MedBiome has developed a novel platform for the identification, screening
and development of microbiome modulators and aims to develop novel microbiome-targeted therapeutic
and nutritional approaches that will improve disease outcomes by stratifying patients to customized
treatments. www.medbiome.ca.

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
MedBiome
Bill Cheliak, CEO
613-717-5102
Contact via Email
www.medbiome.ca

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/804333

News Image:

Page 2/2
PR.com Press Release Distribution Terms of Use